THANK YOU FOR SUBSCRIBING
Deep Longevity specializes in deep learning for aging research specializing in the development of deep biomarkers of aging using clinical blood tests, transcriptomic, proteomic, epigenetic, microbiome, behavioral, wearable, imaging, and multiple other data types
Fremont, CA: Deep Longevity, a San Diego, CA-based biotechnology company poised to improve longevity R&D through AI-discovered biomarkers of aging, closed a seed funding round of undisclosed amount.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The company has recently come out of stealth from Insilico Medicine, the AI for drug discovery company recognized for its breakthroughs in generative biology, and generative chemistry.
The round was led by ETP Ventures and Human Longevity and Performance Impact Venture Fund, with active participation from Longevity Vision Fund, Bold Capital Partners, Oculus co-founder and former chief software architect Michael Antonov through Formic Ventures, and LongeVC, as well as undisclosed investors including celebrity investors in artificial intelligence and some of the most prominent U.S. biotechnology investors.
Led by Alex Zhavoronkov, PhD, founder and CEO, Deep Longevity specializes in deep learning for aging research specializing in the development of deep biomarkers of aging using clinical blood tests, transcriptomic, proteomic, epigenetic, microbiome, behavioral, wearable, imaging, and multiple other data types. The company possesses exclusive licenses to a comprehensive IP portfolio, including both pending and granted patents. In the first collaboration, the company will deploy its technology in a partnership with Human Longevity, a genomics-based health intelligence leader with a large database of phenotypic information, and sequenced genomes.
“Over the past few years, our team made several discoveries in the field of deep learning for longevity research in both biomarkers of aging and geroprotector discovery. Deep Longevity will translate these discoveries into the new industry of longevity management and medicine providing longevity as a service. To enable early access to these technologies we partnered with the most prominent concierge longevity practice, Human Longevity. We are happy to announce this round of funding provided by the top experts in longevity, biotechnology, and artificial intelligence. We will help power their longevity ecosystem with a standardized set of aging and longevity biomarkers,” said Alex Zhavoronkov, PhD, founder, and CEO of Deep Longevity.
See also:
More in News